Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.80 |
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21342528 | 1.00 | FOLH1 (0.80) | FOLH1NAALAD2RIMKLACPB2 | |
| SCHEMBL11986386 | 0.94 | FOLH1 (0.80) | FOLH1NAALAD2RIMKLACPB2 | |
| SCHEMBL18800237 | 0.93 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLACPB2 | |
| SCHEMBL19265779 | 0.89 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLACPB2 | |
| SCHEMBL2450650 | 0.89 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL4669761 | 0.89 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739351 | 0.89 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL2450656 | 0.89 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739333 | 0.89 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15739372 | 0.89 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
| EP-3875082-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | Endocyte, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3858341-A1 | PSMA LIGAND-CONTAINING CONJUGATES FOR THE TREATMENT OF PROSTATE CANCER | Endocyte, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3777898-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190275181-A1 | Compounds for Positron Emission Tomography | ENDOCYTE INC (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3533473-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2010147965-A2 | PROCESS FOR PRODUCTION OF HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275181-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | FOLH1 1/4885NAALAD2 67/4885RIMKLA 110/4885 |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | FOLH1 1/4885NAALAD2 67/4885RIMKLA 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.